Arax Advisory Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Arax Advisory Partners’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-476	Closed	-$1.45K	–	3116
2024 Q4	$1.45K	Buy	476 +267	+128%	+$1.16K	﹤0.01%	2085
2024 Q3	$1.08K	Hold	209	–	–	﹤0.01%	2226
2024 Q2	$538	Buy	+209	New	+$714	﹤0.01%	2319

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Arax Advisory Partners's RVNC Position: Q1 2025 in Review

Arax Advisory Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 476 shares — an estimated $1.45K sold.

Arax Advisory Partners first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $1.45K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Arax Advisory Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Arax Advisory Partners sold 476 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.45K.
Arax Advisory Partners first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
Arax Advisory Partners's Revance Therapeutics, Inc. position peaked at $1.45K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Arax Advisory Partners's 13F filing for Q1 2025, filed 15 May 2025.